.jpeg)
2026-09-10 03:33:16
Tamoxifen is a long-established endocrine therapy for breast cancer. Long-term use requires awareness of venous thromboembolism and endometrial abnormalities. This article outlines key adverse effects and at-risk populations.
2026-09-10 03:00:52
Worsening symptoms or declining cardiac function during acoramidis treatment for ATTR-CM should not be directly labeled as drug resistance. This article explains the mechanism, proper assessment methods, and dosing compliance.
2026-09-10 02:56:36
Lorlatinib has only one formal contraindication (prohibited co-administration with strong CYP3A inducers), but six major safety risks require close attention, including CNS effects, dyslipidemia, and interstitial lung disease.
2026-09-10 02:52:45
A multicenter Ib/II trial shows the azacitidine + venetoclax + ivosidenib triplet regimen achieves 95% ORR in newly diagnosed IDH1-mutant AML with manageable safety.
2026-09-09 07:04:37
Dacomitinib is a second-generation irreversible EGFR TKI for first-line treatment of metastatic NSCLC with EGFR exon 19 deletion or L858R mutation. This article details dosing, switching strategies, comparison with osimertinib, and adverse event management.
2026-09-09 06:37:44
Abemaciclib is a CDK4/6 inhibitor for hormone receptor-positive, HER2-negative breast cancer. This article explains its mechanism, synergy with endocrine therapy, efficacy differences between mono and combination, and precautions when switching from other CDK4/6 inhibitors.
2026-09-08 06:24:42
Fezolinetant is a non-hormonal oral medication for moderate to severe vasomotor symptoms of menopause. This article details standard dosing, missed dose management, and liver function monitoring.
2026-09-08 05:44:22
Lusutrombopag stimulates TPO receptors to raise platelet count, mainly for chronic liver disease patients before invasive procedures. This article details thrombosis risk, common side effects, and the US-approved regimen.
2026-09-08 05:39:33
Mirogabalin is used for neuropathic pain, but its analgesic effect is not immediate. This article explains dose titration, factors affecting onset, and the need for continuous observation.
2026-09-08 05:30:58
Cemiplimab is a PD-1 immune checkpoint inhibitor that blocks PD-1 from binding to PD-L1/PD-L2, releasing T-cell suppression and enabling immune attack on tumors. This article explains its mechanism and clinical indication screening.
2026-09-07 07:24:27
Tivozanib (FOTIVDA) is an oral targeted therapy for renal cell carcinoma, given on a 21-day-on, 7-day-off schedule. This article details standard dosing, hepatic impairment adjustment, hypertension monitoring, and side effect management.
2026-09-07 05:13:58
Does anagrelide worsen myelofibrosis in essential thrombocythemia (ET)? This article reviews clinical evidence, distinguishes drug effects from natural disease progression, and highlights monitoring strategies.
